New Ray Medicine International Holding Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Qiuqin Wang
Chief executive officer
HK$1.2m
Total compensation
| CEO salary percentage | 17.7% |
| CEO tenure | 3.9yrs |
| CEO ownership | n/a |
| Management average tenure | 3yrs |
| Board average tenure | 6yrs |
Recent management updates
Recent updates
Lacklustre Performance Is Driving New Ray Medicine International Holding Limited's (HKG:6108) 34% Price Drop
Jan 26
There's Reason For Concern Over New Ray Medicine International Holding Limited's (HKG:6108) Price
Jun 08We're Keeping An Eye On New Ray Medicine International Holding's (HKG:6108) Cash Burn Rate
Mar 29
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | HK$1m | HK$211k | -HK$22m |
| Sep 30 2023 | n/a | n/a | -HK$46m |
| Jun 30 2023 | n/a | n/a | -HK$70m |
| Mar 31 2023 | n/a | n/a | -HK$74m |
| Dec 31 2022 | HK$2m | HK$222k | -HK$78m |
| Sep 30 2022 | n/a | n/a | -HK$52m |
| Jun 30 2022 | n/a | n/a | -HK$25m |
| Mar 31 2022 | n/a | n/a | -HK$14m |
| Dec 31 2021 | HK$1m | HK$220k | -HK$3m |
| Sep 30 2021 | n/a | n/a | -HK$17m |
| Jun 30 2021 | n/a | n/a | -HK$32m |
| Mar 31 2021 | n/a | n/a | -HK$51m |
| Dec 31 2020 | HK$1m | HK$174k | -HK$70m |
| Sep 30 2020 | n/a | n/a | -HK$71m |
| Jun 30 2020 | n/a | n/a | -HK$73m |
| Mar 31 2020 | n/a | n/a | -HK$58m |
| Dec 31 2019 | HK$874k | HK$198k | -HK$44m |
| Sep 30 2019 | n/a | n/a | -HK$16m |
| Jun 30 2019 | n/a | n/a | HK$11m |
| Mar 31 2019 | n/a | n/a | HK$22m |
| Dec 31 2018 | HK$310k | HK$122k | HK$33m |
Compensation vs Market: Qiuqin's total compensation ($USD152.61K) is below average for companies of similar size in the Hong Kong market ($USD233.14K).
Compensation vs Earnings: Qiuqin's compensation has been consistent with company performance over the past year.
CEO
Qiuqin Wang (46 yo)
3.9yrs
Tenure
HK$1,192,000
Compensation
Ms. Qiuqin Wang serves as Executive Director at New Ray Medicine International Holding Limited since June 27, 2018 and serves as its Chief Executive Officer since July 31, 2020 and serves as its Chairman s...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 3.9yrs | HK$1.19m | no data | |
| Executive Director | 3.9yrs | HK$360.00k | no data | |
| Executive Director | 3yrs | HK$360.00k | no data | |
| Executive Director | 1.3yrs | HK$448.00k | no data | |
| Financial Controller & Company Secretary | less than a year | no data | no data |
3.0yrs
Average Tenure
45yo
Average Age
Experienced Management: 6108's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 6yrs | HK$1.19m | no data | |
| Executive Director | 6yrs | HK$360.00k | no data | |
| Executive Director | 3yrs | HK$360.00k | no data | |
| Executive Director | 1.3yrs | HK$448.00k | no data | |
| Independent Non-Executive Director | 5.8yrs | HK$240.00k | no data | |
| Independent Non Executive Director | 10.8yrs | HK$240.00k | no data | |
| Independent Non-Executive Director | 7yrs | HK$240.00k | no data |
6.0yrs
Average Tenure
46yo
Average Age
Experienced Board: 6108's board of directors are considered experienced (6 years average tenure).